Luminari provides a complete suite of services to help pharmaceutical companies, biotech's and academic researchers accelerate the drug development process. We offer AI, Blockchain and a proprietary virtual patient tool to streamline the process, eliminate errors and redundancies and ensure clinical outcomes are met.

Luminari's AI technology helps to identify potential problems quickly and accurately, allowing for more efficient drug development. Our Blockchain technology helps to ensure data accuracy and security. Our proprietary virtual patient tool allows for more accurate predictions of drug efficacy, reducing the risk of errors.

Oncology, neurology, immunology, rare disease, vaccine and med. device. While these are our core areas of focus, our medical and science team has managed and executed clinical trials in many other therapies, such as ophthalmology, dermatology, and cardiovascular to name a few.

Luminari is headquartered in the suburbs of Chicago. Our satellite offices are located in Miami, New York and Seattle

Public, but we are currently in the process of training our custom GPT which will be available soon.

Our AI algorithms accelerate everything from patient screening to analysis while blockchain heightens data transparency. This powers faster, more robust trials.

Multiple reviews, external audits, and ethics boards ensure our tech integrations uphold the highest privacy and fairness standards.

Absolutely. Our unified platform enables seamless global coordination, site management, and remote monitoring capabilities.

Yes, our specialized teams guide assets from preclinical planning through commercialization to provide integrated operational efficiencies.

We concentrate on ethical data integrations, predictive analytics, enrollment algorithms, and blockchain compensation models that put patients first.

Our growing, global site partnership network plus AI matching with EHR data significantly cuts enrollment times to accelerate trial progress.

Definitely. Our experts leverage data-driven disease insights to collaboratively build ideal protocols and minimize amendment needs.

Currently we support Neurology and Dermatology.

In the near future our therapeutic expertise will include Oncology, CNS, AI, MS and other therapies.

Our dedicated GXP quality team guides clients through VIPPS frameworks and GAMP compliance from study design through closeouts.

Our unified platform centralizes workflows across functions into an easy-to-navigate portal to avoid coordination overload.

Absolutely - our analytics engines transform RWE into actionable insights to refine trial designs, enrollment criteria, and more.

Yes. Our teams guide assets from clinical positioning to payer landscape modeling to reimbursement strategy development. Having launched over 35 products globally, across a variety of therapies and disease states, Luminari can help with even the most complex drug commercialization efforts. Additionally, Luminari has partnered with a number of organization to help our clients with MAH registration globally.

Our partners cite our patient focus, ethical technology, and collaborative nature as key loyalty drivers.